Followers | 3817 |
Posts | 241280 |
Boards Moderated | 0 |
Alias Born | 07/30/2007 |
Tuesday, October 10, 2017 3:01:48 PM
Roka Bioscience (ROKA) surged 153% to their highest level in more than two months -- piercing their 50- and 100-day moving averages for the first time since April -- in the wake of a disclosure Edward Painter, CEO of A2A Pharmaceuticals, has acquired 340,000 shares of Roka, or 6.79%. "Edward Painter purchased shares with the intention of seeking a business combination with A2A Pharmaceuticals, a private biotechnology company," according to a regulatory statement. "He may sell shares or buy additional shares or change his purpose of transacting in the future." Roka sold substantially all of its assets in August to a subsidiary of Institute for Environmental Health for $17.5 million in cash, the initial step in a contemplated liquidation of the molecular diagnostics company.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM